Aardvark Therapeutics, Inc. Common Stock (AARD) stock forecast · $284.4M cap
Aardvark Therapeutics, Inc. Common Stock (AARD) is a biotechnology company listed on US.
This AARD forecast page states what the cached financials imply — not a price target and not a guarantee. Aardvark Therapeutics, Inc. Common Stock outlooks on Lician start from reported revenue and the latest filing, then you decide.
Latest reported AARD revenue for 2025-12-31 was $0. Net income was -$57.6M. Revenue was down 100.0% from 2024-12-31 to 2025-12-31. AARD currently screens at market cap $284.4M.
The near-term path: Revenue was down 100.0% from 2024-12-31 to 2025-12-31. A forecast that ignores that change is just a story.
AARD currently screens at market cap $284.4M. Stretching today's multiple into 2026 without a filing reason is how thin forecast pages get ignored.
When the next AARD 10-Q or 8-K lands, this outlook should move. Until then the SEC page is the source.
Not a prediction market. For the live quote and the full model, use the AARD stock page.
Not investment advice.